ReviewJournal of gastroenterology2015
A breakthrough in probiotics: Clostridium butyricum regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease.
Review in Journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 147 citations in OpenAlex.
- Trial
- Lactobacillus brevis cell-free supernatant attenuates inflammation-associated gene expression and differentially modulates host defense-associated genes in DSS-stimulated HT-29 cells.Molecular biology reports · 2026Article
- The Effect of Multi-Strain Probiotics, Zinc and Copper on the Performance of Broiler Chickens Challenged With Clostridium perfringens.Veterinary medicine and science · 2026Article
- Adolescent Dietary Supplementation of Omega-3 Polyunsaturated Fatty Acids Alleviates PTSD-Like Fear Memory and Affective Dysregulation in Rats.Smart medicine · 2026Article
- Lack of genotoxicity and subchronic toxicity in safety assessment studies of aToxicology reports · 2026Article
- Gut Microbiota and Interorgan Communication Among the Gut, Brain, and Beyond.Internal medicine (Tokyo, Japan) · 2026Review
- Clostridium butyricum Regulates the Inflammatory and Immunoregulatory Pathway Through NFKB1 in Colorectal Cancer Treatment.Probiotics and antimicrobial proteins · 2026Article
- Inference of causal interaction networks of gut microbiota using transfer entropy.BMC genomics · 2025Article
- Towards an Asian paradigm of inflammatory bowel disease management: A comparative review of China and Japan.Intractable & rare diseases research · 2025Review
- Comparative genomics ofMicrobial genomics · 2025Article
- Evolving Dynamics of Fermented Food Microbiota and the Gut Microenvironment: Strategic Pathways to Enhance Human Health.Foods (Basel, Switzerland) · 2025Review
- Efficacy ofMicroorganisms · 2025Review
- Survival and Morphological Changes ofMicroorganisms · 2025Article
- Oral Combined Probiotics Clostridium butyricum and Akkermansia muciniphila Inhibits the Progression of 4T1 Breast Cancer by Activating Bcl-2/Bax Pathway.Cancer medicine · 2025Article
- Butyrate: a key mediator of gut-brain communication in Alzheimer's disease.Metabolic brain disease · 2025Review
- Elucidating the critical role of gut microbiota in the pathogenesis of bacterial pneumonia: insights from a Mendelian randomization analysis mediated by immune cell.BMC infectious diseases · 2025Article
- The Gut Microbiota Characterization of a World-Class Mountain Trail Runner During a Complete Competition Season: A Case Report.Journal of athletic training · 2025Article
- Review
- Detection of Antimicrobial Proteins/Peptides and Bacterial Proteins Involved in Antimicrobial Resistance in Raw Cow's Milk from Different Breeds.Antibiotics (Basel, Switzerland) · 2024Article
- Effects of Long-Term Coated Sodium Butyrate Supplementation on the Intestinal Health and Colonization of CecalAnimals : an open access journal from MDPI · 2024Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal immune homeostasis is regulated by gut microbiota, including beneficial and pathogenic microorganisms. Imbalance in gut bacterial constituents provokes host proinflammatory responses causing diseases such as inflammatory bowel disease (IBD). The development of next-generation sequencing technology allows the identification of microbiota alterations in IBD. Several studies have shown reduced diversity in the gut microbiota of patients with IBD. Advances in gnotobiotic technology have made possible analysis of the role of specific bacterial strains in immune cells in the intestine. Using these techniques, we have shown that Clostridium butyricum as a probiotic induces interleukin-10-producing macrophages in inflamed mucosa via the Toll-like receptor 2/myeloid differentiation primary response gene 88 pathway to prevent acute experimental colitis. In this review, we focus on the new approaches for the role of specific bacterial strains in immunological responses, as well as the potential of bacterial therapy for IBD treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.